… Pharmacokinetic and Pharmacodynamic Modelling Expert ProQR Therapeutics is a NASDAQ-listed biotechnology company … with an office in and Cambridge, Massachusetts, USA. At ProQR, we are on a mission to edit RNA, treat disease and change lives. A team of 180+ enthusiastic ProQRians from all walks of life and more than 30 different …
… Principal Scientist Liver ProQR Therapeutics is a NASDAQ-listed biotechnology company … with an office in and Cambridge, Massachusetts, USA. At ProQR, we are on a mission to edit RNA, treat disease and … modeling. Collaborate closely with internal teams (R&D, Clinical Operations) and external partners (CROs, …
… Head of Biomarkers ProQR Therapeutics is a NASDAQ-listed biotechnology company … with an office in and Cambridge, Massachusetts, USA. At ProQR, we are on a mission to edit RNA, treat disease and change lives. A team of 180+ enthusiastic ProQRians from all walks of life and more than 30 different …
… Head of Clinical Quantitative Science ProQR Therapeutics is a NASDAQ-listed biotechnology company … with an office in and Cambridge, Massachusetts, USA. At ProQR, we are on a mission to edit RNA, treat disease and … with statistical software and modeling tools (e.g., R, SAS, Python , Bayesian frameworks). Proven success in …
This virtual event on March 29, 2023 featured presentations by ProQR Management on the company's proprietary Axiomer® RNA editing technology platform, detailed the initial pipeline targets, and provided guidance on the advancement of programs toward the clinic. ProQR also reported its 2022 year-end financials and the extension of its cash runway guidance.
This is Gerard Platenburg's presentation at the 5th International Conference on Base Editing, Prime Editing & Related Enzymes (Deaminet 2024) in San Diego, California.
Development of RNA Base Editing Technologies for Precision Medicines with Axiomer® and Trident® presented at TIDES USA 2022 by Gerard Platenburg - ProQR Therapeutics.
Axiomer® platform applicability and potential in therapeutically relevant models for targeted RNA editing presented at TIDES EU 2018 by Antti Aalto - ProQR Therapeutics
